Fujimura M, Nakatsuji Y, Ishimaru H
Pol J Vet Sci. 2016 Sep 1;19(3):567-572. doi: 10.1515/pjvs-2016-0071.
In this study, dogs were separated into two groups and treated with immunosuppressant (Cyclosporin A: CsA). The first group was the canine atopic dermatitis (CAD) group, which is similar to extrinsic atopic dermatitis (AD) in humans (treated with a CsA dose of 2.5-5.5 mg/kg, n=8), and the second group was the canine atopic-like dermatitis (ALD) group, which is similar to intrinsic AD in humans (treated with a CsA dose of 2.5-6.5 mg/kg, n=14). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (PRE) and after treatment (POST) to assess the effectiveness of CsA for the two groups. In the CAD group, CADESI-4 showed no change (PRE:79±29, POST:77±28) and out of the eight dogs, no dogs showed complete remission, three dogs showed partial remission, and five dogs showed no effect. Whereas in the ALD group, CADESI-4 showed a significant reduction (PRE: 61±42, POST: 32±25, p<0.01) and out of the 14 dogs, 11 dogs showed complete remission, two dogs showed partial remission, and one dog showed no effect. The results indicate that the immunosuppressant showed effectiveness for the dogs diagnosed with ALD. One dog had to be treated for a year and eight months, which was the longest period in the study, this dog presented with hyperplasia of the lymphoidgland and mammary tumor.
在本研究中，将犬分为两组并用免疫抑制剂（环孢素A：CsA）进行治疗。第一组为犬特应性皮炎（CAD）组，类似于人类的外源性特应性皮炎（AD）（用2.5 - 5.5mg/kg的CsA剂量治疗，n = 8），第二组为犬类特应性皮炎（ALD）组，类似于人类的内源性AD（用2.5 - 6.5mg/kg的CsA剂量治疗，n = 14）。在治疗前（PRE）和治疗后（POST）评估犬特应性皮炎范围和严重程度指数（CADESI）-4，以评估CsA对两组的疗效。在CAD组中，CADESI - 4没有变化（PRE：79±29，POST：77±28），8只犬中，没有犬完全缓解，3只犬部分缓解，5只犬无效。而在ALD组中，CADESI - 4显著降低（PRE：61±42，POST：32±25，p<0.01），14只犬中，11只犬完全缓解，2只犬部分缓解，1只犬无效。结果表明，免疫抑制剂对诊断为ALD的犬有效。有1只犬必须治疗1年零8个月，这是研究中最长治疗期，该犬出现了淋巴结增生和乳腺肿瘤。
